Physician profile
Jinzhu Li
NPI 1720373343
$1,118.64
in general payments reported to CMS, 2019-2025
18 companies · $392 in 2025
The $392 reported for 2025 was less than what a typical Clinical & Laboratory Immunology (Allergy & Immunology) provider received nationally (typical 2025 total: $1,390).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $110 · 2020: $22.05 · 2021: $33.10 · 2022: $120 · 2023: $103 · 2024: $339 · 2025: $392.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $833.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $833.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $157.94 | 2022-2025 | Tezspire, Fasenra |
| Csl Behring | $124.29 | 2020-2025 | Haegarda, Hizentra |
| Genentech USA, INC. | $107.47 | 2024-2025 | Xolair |
| Kaleo, INC. | $106.71 | 2019-2024 | Auvi-Q |
| Glaxosmithkline, LLC. | $103.67 | 2019-2025 | Nucala |
| Genzyme Corporation | $82.52 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $76.16 | 2024-2025 | Cuvitru, Eohilia |
| Novartis Pharmaceuticals Corporation | $55.63 | 2019-2025 | |
| Biocryst US Sales Co., LLC | $46.00 | 2025 | Orladeyo |
| Pharming Healthcare, INC. | $41.26 | 2024-2025 | Ruconest |
| Grifols USA, LLC | $39.63 | 2019-2024 | Xembify |
| Pfizer INC. | $38.58 | 2025 | |
| Optinose US, INC. | $36.79 | 2024 | |
| Kedrion Biopharma, INC. | $36.43 | 2024 | Kedrab, Koate, Gammaked |
| Amgen INC. | $28.25 | 2023 | Tezspire |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $18.99 | 2025 | Nemluvio |
| Aytu Biopharma, INC. | $18.32 | 2024 | Karbinal |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jinzhu Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.